11 GHP Q3 2025 As many first primary care providers are not equipped with the necessary tools and training to accurately identify which moles or lesions are cancerous, or which are not, due to hundreds of millions of benign melanoma mimics, there are specific challenges within the healthcare system. The main issue is the sheer amount of skin cancer, including 100,000 invasive melanomas diagnosed each year in America alone, which makes this process like finding a needle in the hay stack – when all the hay looks like needles. The other impactful issue is the strain on primary healthcare staff who are trying to treat every patient with a premium level of care regardless of the overwhelming pressure. With so many patients not only worried about skin cancer, general practitioners and specialists aren’t always able to catch things soon enough. The waiting times are long for dermatology appointments, if the general practitioner has all the tools they need to successfully diagnose a risk and process a referral to dermatology. This system, of general practitioners almost vetting each case to ensure they’re directed to the right department or specialist, can ultimately cost a lot of time – which is of the highest value especially when dealing with cancer. DermaSensor is on a mission to empower healthcare professionals with data-driven breakthrough solutions, with proven early skin cancer detection technology, to save lives. With hundreds of millions of skin lesions and moles which are completely normal and non-cancerous, and hundreds of millions which aren’t, the stakes are high and the healthcare system is in need of a tool that can take charge and change the process completely. This is exactly where DermaSensor comes in. It is the first and only tool for primary care providers or non-dermatologists which helps individuals to assess suspicious moles or lesions on the spot as we’ve never seen before. As many of us find a suspicious mole and are asked to keep an eye on the growth, although it may even be benign, the running risk is that it is or becomes cancerous and we have no real way of telling until we manage to see a dermatologist. Of course, dermatologists are specialist healthcare professionals who have specifically trained in one area of expertise, with base knowledge of overall health, whereas general practitioners have a base knowledge across a plethora of areas but do not have the There are two main challenges that cancer detection faces: the ineffective process of evaluating moles or lesions, and the prolonged wait for dermatology appointments. However, we’ve found a company – and innovative device – combatting both of these challenges. We take a closer look at DermaSensor, Inc. as it wins the esteemed title of Best Skin Cancer Detection Technology Company 2025 – USA. Award-Winning AI-Driven Precision for Cancer Detection experience needed to ensure their diagnoses are completely accurate for each and every skin issue. DermaSensor brings its background of experience and innovation to the forefront of the industry so that healthcare professionals and their patients can thrive. Having such a huge impact on the healthcare industry across America, and soon beyond, DermaSensor’s achievements and delivery of its life-changing technology is the company’s unique selling point. However, the team behind the technology continues to work on all the necessary research and development along with labor towards regulations, certification, and sustained technological innovation, ensuring that this unique selling point is something that not only carries on into the future, but leaves a legacy as the first company to push this technology forward into the world. With any changing algorithms, as the years go by, DermaSensor will ensure that it is always regulated by the FDA and that the DermaSensor tool stays at the very cutting edge of the industry. For the future ahead, DermaSensor plans on having 15,000 devices in use by 2030 in the US. The company will eventually be able to push for use across Europe and beyond, to ensure that people all around the world can have access to life saving technology which not only helps them to avoid a long journey with cancer but also to alleviate the stress and strain on the global healthcare industry. It’s an honor to award DermaSensor with its accolade in our Global Excellence Awards this year, and we’re looking forward to seeing what the company achieves in the years to come. Contact: Keller Sharp Company: DermaSensor, Inc. Website: https://www.dermasensor.com/
RkJQdWJsaXNoZXIy MTUyMDQwMA==